Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.
Unbeatable Production Arbitrage
- Ultra-Low Costs: All-in production costs of €0.30 per gram, with further downward pressure expected as the facility scales toward its 25+ tonne licensed capacity.
- Elite Genetics: Proven high-THC cultivars (mid-20% THC) featuring advanced terpene profiles tailored for European and Australian markets.
- Ideal Climate: Located in a premium microclimate with stable, predictable conditions enabling year-round cultivation.
Institutional-Grade Infrastructure & Scalability
- Immediate Capacity: 1.7 hectares of interconnected greenhouses currently producing 5.7 tonnes of dried flower annually.
- Expansion Ready: Fully licensed 15-hectare site with capacity for 25+ tonnes, enabling significant scale-up with minimal additional capex.
- Operational Autonomy: Dedicated on-site power substation with diesel backup and a 20,000 m³ rainwater reservoir supported by a sophisticated water treatment system.
Advanced Post-Harvest & Processing Technology
- Dual-Track Facility: Separate buildings for GACP post-harvest and EU-GMP / TGA GMP-compliant processing.
- Unique Technology Edge: Includes Colombia’s only PLC 2500 purification system and an X-ray sterilization unit required for the Australian market.
- On-Site Laboratory: Fully equipped lab enabling real-time potency and purity testing to ensure pharmaceutical-grade standards.
Validated Global Export Track Record
- Proven Market Access: One of the few Colombian producers with established exports; approximately 1 tonne already delivered to European markets.
- De-Risked Revenue: Sale includes a binding 3-year offtake agreement and established distribution relationships in Germany and the UK.
Turnkey Transition & Strategic Value
- Investment Value: Over USD $12M already invested in infrastructure, licensing, and elite genetics.
- Financial Status: Debt-free; all related-party debt is forgiven at closing.
- Shortcut to Market: Bypasses the typical 3-year development cycle including site selection, construction, and regulatory approvals in Colombia.
- Management Continuity: Core leadership team, including production specialists, will remain to ensure a seamless operational transition.
- Tax Efficiency: Tax loss carryforwards (~USD $1.5M) available through 2036, preserved under the share sale structure.
Financial Forecast
| Parameter / Metric |
Conservative Scenario |
Base Scenario |
Optimistic Scenario |
| Asking / Target Price |
TBD (On Request) |
TBD (On Request) |
TBD (On Request) |
| Annual Finished Extraction Capacity |
~5,000 kg |
~8,000 kg |
~12,000 kg |
| Average Export Price / Gram (EU GMP) |
$2.50 / g |
$3.50 / g |
$4.50 / g |
| Estimated Gross Revenue |
~$12,500,000 USD |
~$28,000,000 USD |
~$54,000,000 USD |
| Estimated Production & OPEX |
~$6,500,000 USD |
~$12,000,000 USD |
~$21,000,000 USD |
| Estimated EBITDA |
~$6,000,000 USD |
~$16,000,000 USD |
~$33,000,000 USD |
| EBITDA Margin |
~48% |
~57% |
~61% |